Dangers of Excess Estrogen In the Aging MaleNovember 2008
By William Faloon
How Excess Estrogen Levels Occur in Aging Men
In males, the main biologically active estrogen is estradiol. The primary source of estradiol in men is from the conversion (aromatization) of testosterone. As men age, the production of androgens from the adrenals and gonads is decreased. The aromatization of testosterone to estradiol is often maintained, but due to a variety of factors, more testosterone is aromatized in fatty tissues, causing a further imbalance of the ratio of testosterone to estrogen, i.e. too much estradiol and not enough testosterone. The result is a deficiency of beneficial testosterone and an excess amount of estradiol.34
As men age, the amount of testosterone produced in the testes diminishes greatly. Yet estradiol levels remain persistently high. The reason for this is increasing aromatase activity along with age-associated fat mass, especially in the belly.5 Estradiol levels correlate significantly to body fat mass and more specifically to subcutaneous abdominal fat. The epidemic of abdominal obesity observed in aging men is associated with a constellation of degenerative disorders, including heart disease, diabetes, and cancer.9,35-38
Subcutaneous abdominal fat acts as a secretory gland, often producing and emitting excessive levels of estradiol into an aging man’s blood.39 One’s waist circumference is a highly accurate prognostic measurement of future disease risk, with excess estradiol secretion being at least one of the deadly mechanisms associated with the difficult-to-resolve problem of having too much abdominal fat.5,40
Symptoms of excess estrogen in aging men include the development of breasts, having too much abdominal weight, feeling tired, suffering loss of muscle mass, and having emotional disturbances. Many of these symptoms correspond to testosterone deficiency as well.41
Don’t Lower Your Estrogen Too Much!
When reviewing the studies about the multiple pathological effects of excess estrogen in aging men, it may be tempting to take high doses of an aromatase-inhibiting drug (like Arimidex®) to slash estrogen levels as low as possible. Don’t do this, as men need estrogen to maintain bone density, cognitive function, and even to maintain the inner lining of the arterial wall (the endothelium).42
Most Life Extension members know that too little cholesterol (below 150 mg/dL) can be more dangerous than too much cholesterol (levels over 200 mg/dL). The same may hold true for estrogen. We have recommended that ideal ranges for estradiol for most aging men are between 20 and 30 pg/mL of blood. Below 18 pg/mL increases osteoporosis risk, while levels greater than 30 pg/mL increase heart attack and stroke incidence.
The availability of low-cost blood tests enables aging men to optimize their estradiol levels using natural approaches and/or prescription drugs.
Estrogen and Men’s Bones
Osteoporosis is not just a risk for aging women. Men also suffer crippling fractures caused by loss of bone mineral density. When aged men suffer a bone fracture, their risk of dying is significantly higher than women.43,44
In a study published two years ago, doctors analyzed blood levels in three groups of men for estradiol only, testosterone only, and estradiol and testosterone together. In men with low estradiol (2.0-18.1 pg/mL of blood), hip fractures were more than three times higher compared with men who had estradiol levels of 18.2-34.2 pg/mL.45
Men with estradiol levels greater than 34.3 pg/mL had a slightly higher risk of hip fracture compared with those in the range of 18.2-34.2 pg/mL. This study helps confirm Life Extension’s recommended range for estrogen levels in aging men.
Interestingly, this study also showed in the group of men whose blood was measured for estradiol and testosterone, those who were low in both these hormones suffered a startling 6.5 times greater incidence of hip fractures. The authors of this study concluded, “men with low estradiol levels are at an increased risk for future hip fracture. Men with both low estradiol and low testosterone levels seem to be at greatest risk for hip fracture.”45
With the voluminous amount of scientific studies being published today, contradictions inevitably arise, and this is not always due to study design flaws.
For the past decade, Life Extension has reported on dozens of studies showing that higher testosterone levels significantly reduce a man’s risk of cardiovascular disease. In fact, we just did a comprehensive database search and identified a total of 50 studies that document the protective effects of testosterone against cardiovascular disease in men.
A study published two years ago, however, contradicts this. This study showed greater incidences of heart attacks in men with higher testosterone and lower heart attack risks in older men with higher estradiol. (In younger men, estradiol level had no impact on heart attack incidence in this study.) The authors of the study admitted a limitation to the study was only measuring baseline levels of hormones. This study nonetheless was used at the anti-aging conference to proclaim that estradiol protects against heart attack.46
There are scientific studies that demonstrate estrogen’s potential beneficial effects to a man’s vascular system. These protective mechanisms, however, have to be weighed against pathological damage the very same estrogen can induce.
As I mentioned earlier, despite the documented dangers of excess estrogen, levels that are too low also present risks, not only to bone,45,47-49 but to the vascular system as well.46,50,51 If a man were to intentionally lower his estradiol too much, he could very well suffer vascular disease because estrogen is vital to proper endothelial function.52,53
This is why it is so important for aging men to have annual blood tests. If estrogen is too low (below 18-20 pg/mL), or too high (above 30 pg/mL), corrective action should be taken.
How to Reduce Excess Estrogen
In aging men, a large percentage of estradiol is synthesized in abdominal adipose (fat) tissues.42 Reducing waist circumference confers huge health benefits, one being a lowering of estradiol levels.
One of the most effective ways for men to reduce belly fat is to restore their free testosterone to youthful ranges. Nutrients that inhibit the aromatase enzyme can help boost testosterone levels by preventing its conversion (aromatization) into estradiol.
As men grow older, however, their testicular testosterone production declines precipitously. This means that inhibiting aromatase might not sufficiently maintain testosterone levels because not enough is being produced internally. Fortunately, low-cost compounded testosterone creams are available that can be rubbed on the skin for absorption into the bloodstream.
For men with excess aromatase activity, this topically absorbed testosterone might convert into too much estradiol. If this happens, the use of very low-dose aromatase-inhibiting drugs (0.5 mg of Arimidex® twice a week) may be all that is needed to protect against estrogen overload. Some men don’t need these drugs and can use nutrient formulas that have aromatase-inhibiting properties.
There is no need to guess what you need, as a blood test taken 30-45 days after initiating testosterone-replacement not only reveals a man’s estradiol level, but also ensures that the PSA has not spiked (indicating possible pre-existing prostate cancer), that the dose of testosterone cream is appropriate, and that there are no other side effects occurring.
To view a wide range of estrogen-lowering strategies, one can view Life Extension’s Male Hormone Restoration Protocol.
What if Your Estrogen Level is Too Low?
Some men are so deficient in aromatase that they do not make enough estrogen.
If a blood test reveals estradiol below 20 pg/mL, which may occur if Arimidex®, for example, is being taken at too high a dose, one should consider reducing the dose. Alternatively, applying a tiny dose of a compounded topical estradiol cream to the skin several times a week may also help increase estradiol levels. Follow-up blood tests 30-45 days later can assess if too much or too little topical estradiol cream is being used.
There is also evidence that consuming phytoestrogens from soy might provide similar benefits for the bone75-79 and vascular system.80-88
It is hard to imagine that before 1906, doctors did not even know that a hormone (estrogen) was secreted by the ovaries in women. It was not until 1930 that the isolation of the estrogen complex in pure form was published.
Less than 80 years later, scientists are debating what the optimal levels of estrogen should be in men. This exponential leap in scientific knowledge is a marvel in itself!
The role that estrogen plays in men’s health is an important topic discussed at medical conferences today. As outlined in this article, testing one’s estradiol level is critical because it can be a serious problem if it is too high or if it is too low.
I am pleased to announce that the everyday low price for the Male or Female Blood Test Panels has been reduced from $299 to $269. This price reduction is made possible by the large volume of blood testing Life Extension members have been ordering.
In addition to estradiol, the Male Panel measures PSA, free testosterone, DHEA, C-reactive protein, homocysteine, along with cholesterol lipids, glucose, and blood cell counts and chemistries.
I encourage any member who has not had this comprehensive blood test conducted over the past 12 months to take advantage of this new lower price. To order the Male or Female Panel by phone, call 1-800-208-3444.
If the results reveal estradiol levels are too high or too low, corrective measures can easily be taken to protect your precious health.
1. Colmou A. Estrogens and vascular thrombosis. Soins Gynecol Obstet Pueric Pediatr. 1982 Sep;(16):39-41.
2. Abbott RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in elderly men. Neurology. 2007 Feb 20;68(8):563-8.
3. Tivesten A, Hulthe J, Wallenfeldt K, et al. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab. 2006 Nov;91(11):4433-7.
4. Mohamad MJ, Mohammad MA, Karayyem M, Hairi A, Hader AA. Serum levels of sex hormones in men with acute myocardial infarction. Neuro Endocrinol Lett. 2007 Apr;28(2):182-6.
5. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg, I. Estradiol in elderly men. Aging Male. 2002 Jun;5(2):98-102.
6. Dunajska K, Milewicz A, Szymczak J, et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004 Sep;7(3):197-204.
7. Wranicz JK, Cygankiewicz I, Rosiak M, et al. The relationship between sex hormones and lipid profile in men with coronary artery disease. Int J Cardiol. 2005 May 11;101(1):105-10.
8. Tivesten A, Mellstrom D, Jutberger H, et al. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol. 2007 Sep 11;50(11):1070-6.
9. Tengstrand B, Carlstrom K, Fellander-Tsai L, Hafstrom I. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation. J Rheumatol. 2003 Nov;30(11):2338-43.
10. Stork S, Bots ML, Grobbee DE, van der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med. 2008 Mar 12.
11. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause. 2006 Jul;13(4):643-50.
12. Hemelaar M, Kenemans P, Schalkwijk CG, Braat DD, van der Mooren MJ. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. Hum Reprod. 2006 Jun;21(6):1635-42.
13. Tripathi Y, Hegde BM. Serum estradiol and testosterone levels following acute myocardial infarction in men. Indian J Physiol Pharmacol. 1998 Apr;42(2):291-4.
14. Pugh PJ, Channer KS, Parry H, Downes T, Jone TH. Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocr Res. 2002 Aug;28(3):161-73.
15. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer. 2008 May;44(7):928-36.
16. Ellem SJ, Risbridger GP. Aromatase and prostate cancer. Minerva Endocrinol. 2006 Mar;31(1):1-12.
17. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann NY Acad Sci. 2006 Nov;1089:286-301.
18. Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann NY Acad Sci. 2006 Nov;1089:168-76.
19. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170-83.
20. Ho CK, Nanda J, Chapman KE, Habib FK. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol. 2008 Jun;197(3):483-91.
21. Lowsley OS. The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. Am J Anat. 1912;13:299-348.
22. Prins GS. Development of the prostate. In: Haseltine F, Paulsen C, Wang C, editors. Reproductive Issues and the Aging Male. New York: Embryonic, Inc;1993: 101-12.
23. Prins GS, Birch L, Couse JF, et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res. 2001 Aug 15;61(16):6089-97.
24. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol. 2007 Apr;23(3):374-82.
25. Prins GS, Tang WY, Belmonte J, Ho SM. Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):134-8.
26. Ho SM, Tang WY, Belmonte de Fausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 2006 Jun 1;66(11):5624-32.
27. Rajfer J, Coffey DS. Effects of neonatal steroids on male sex tissues. Invest Urol. 1979 Jul;17(1):3-8.
28. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer. 1988 Feb;57(2):216-8.
29. Giton F, de la Taille A, Allory Y, et al. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):158-67.
30. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008 Mar;73(3):233-44.
31. Scarano WR, Cordeiro RS, Goes RM, Carvalho HF, Taboga SR. Tissue remodeling in Guinea pig lateral prostate at different ages after estradiol treatment. Cell Biol Int. 2005 Sep;29(9):778-84.
32. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori. 2004 Apr;52(4):291-4.
33. Rohrmann S, Nelson WG, Rifai N, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007 Apr;69(4):708-13.
34. Vermeulen A. Androgen replacement therapy in the aging male—a critical evaluation. J Clin Endocrinol Metab. 2001 Jun;86(6):2380-90.
35. Choi BG, McLaughlin MA. Why men’s hearts break: cardiovascular effects of sex steroids. Endocrinol Metab Clin North Am. 2007 Jun;36(2):365-77.
36. Kaneda Y, Ohmori T. Relation between estradiol and negative symptoms in men with schizophrenia. J Neuropsychiatry Clin Neurosci. 2005;17(2):239-42.
37. Zou B, Sasaki H, Kumagai S. Association between Relative Hypogonadism and Metabolic Syndrome in Newly Diagnosed Adult Male Patients with Impaired Glucose Tolerance or Type 2 Diabetes Mellitus. Metab Syndr Relat Disord. 2004;2(1):39-48.
38. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. J Med. 2002;33(1-4):73-86.
39. Kula K, Walczak-Jedrzejowska R, Slowikowska-Hilczer J, et al. Important functions of estrogens in men—breakthrough in contemporary medicine. Przegl Lek. 2005;62(9):908-15.
40. Anderson LA, McTernan PG, Barnett AH, Kumar S. The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and site. J Clin Endocrinol Metab. 2001 Oct;86(10):5045-51.
41. Lund BC, Bever-Stille KA, Perry PJ. Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy. 1999 Aug;19(8):951-6.
42. Gooren LJ, Toorians AW. Significance of oestrogens in male (patho)physiology. Ann Endocrinol (Paris). 2003 Apr;64(2):126-35.
43. Seeman E. The dilemma of osteoporosis in men. Am J Med. 1995 Feb 27;98(2A):76S-88S.
44. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999 Mar 13;353(9156):878-82.
45. Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med. 2006 May;119(5):426-33.
46. Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1;145(3):176-84.
47. Nuti R, Martini G, Merlotti D, et al. Bone metabolism in men: role of aromatase activity. J Endocrinol Invest. 2007;30(6 Suppl):18-23.
48. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab. 2004 Dec;89(12):5898-907.
49. Khosla S, Melton LJ 3rd, Riggs BL. Estrogens and bone health in men. Calcif Tissue Int. 2001 Oct;69(4):189-92.
50. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab. 2005 May;90(5):2708-11.
51. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 Jun 10;340(23):1801-11.
52. Sader MA, McCredie RJ, Griffiths KA, et al. Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clin Endocrinol (Oxf). 2001 Feb;54(2):175-81.
53. Sudhir K, Komesaroff PA. Clinical review 110: Cardiovascular actions of estrogens in men. J Clin Endocrinol Metab. 1999 Oct;84(10):3411-5.
54. Traka M, Gasper AV, Melchini A, et al. Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS ONE. 2008;3(7):e2568.
55. Kirsh VA, Peters U, Mayne ST, et al. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst. 2007 Aug 1;99(15):1200-9.
56. Xiao D, Singh SV. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res. 2007 Mar 1;67(5):2239-46.
57. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005 Nov 10;23(32):8152-60.
58. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1403-9.
59. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer. 2002;42(1):1-9.
60. Grainger EM, Schwartz SJ, Wang S, et al. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer. 2008 Mar;60(2):145-54.
61. Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE. Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr. 2007 Aug;98(2):388-96.
62. Kurahashi N, Iwasaki M, Sasazuki S, et al. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45.
63. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol. 2005 Jan;15(1):17-22.
64. Lee MM, Gomez SL, Chang JS, et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8.
65. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005 Sep;4(9):1201-15.
66. Garikapaty VP, Ashok BT, Chen YG, et al. Anti-carcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer. Oncol Rep. 2005 Jan;13(1):89-93.
67. Sarkar FH, Li Y. Indole-3-carbinol and prostate cancer. J Nutr. 2004 Dec;134(12 Suppl):3493S-8S.
68. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 2001 May 24;20(23):2927-36.
69. Yao H, Wang H, Zhang Z, et al. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer. 2008 Sep 15;123(6):1255-61.
70. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood). 2007 Feb;232(2):227-34.
71. Zhang LL, Li L, Wu DP, et al. A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol Sin. 2008 Sep;29(9):1060-8.
72. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008 May 18.
73. Kikuno N, Shiina H, Urakami S, et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer. 2008 Aug 1;123(3):552-60.
74. Nagata Y, Sonoda T, Mori M, et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007 Aug;137(8):1974-9.
75. Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2008 Feb;62(2):155-61.
76. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2004 Feb;79(2):326-33.
77. Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt). 2004 Nov;13(9):1000-7.
78. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal japanese women: a four-week study. J Am Coll Nutr. 2002 Apr;21(2):97-102.
79. Droke EA, Hager KA, Lerner MR, et al. Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease. J Inflamm (Lond). 2007;417.
80. Seok YM, Baek I, Kim YH, et al. Isoflavone attenuates vascular contraction through inhibition of the RhoA/Rho-kinase signaling pathway. J Pharmacol Exp Ther. 2008 Sep;326(3):991-8.
81. Si H, Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem. 2007;14(24):2581-9.
82. Colacurci N, Chiantera A, Fornaro F, et al. Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause. 2005 May;12(3):299-307.
83. Liang YL, Teede H, Dalais F, McGrath BP. The effects of phytoestrogen on blood pressure and lipids in healthy volunteers. Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Aug;34(8):726-9.
84. Kapiotis S, Hermann M, Held I, et al. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2868-74.
85. Wenzel U, Fuchs D, Daniel H. Protective effects of soy-isoflavones in cardiovascular disease. Identification of molecular targets. Hamostaseologie. 2008 Feb;28(1-2):85-8.
86. Si H, Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J Nutr. 2008 Feb;138(2):297-304.
87. Chan YH, Lau KK, Yiu KH, et al. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr. 2007 Oct;86(4):938-45.
88. Rimbach G, Boesch-Saadatmandi C, Frank J, et al. Dietary isoflavones in the prevention of cardiovascular disease--a molecular perspective. Food Chem Toxicol. 2008 Apr;46(4):1308-19.